We are live on ! Find out more
CARM

Carisma Therapeutics
CARM

Delisted

CARM was delisted on the 10th of October, 2025.

Back to rankings

70 hedge funds and large institutions have $19.8M invested in Carisma Therapeutics in 2022 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 8 increasing their positions, 24 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more capital invested

Capital invested by funds: $11M → $19.8M (+$8.8M)

18% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 11

3% more funds holding

Funds holding: 68 → 70 (+2)

4% more call options, than puts

Call options by funds: $1.14M | Put options by funds: $1.09M

0.16% more ownership

Funds ownership: 0.64% → 0.8% (+0.16%)

67% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 24

Holders
70
Holders Change
+2
Holders Change %
+2.94%
% of All Funds
1.13%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
13
Increased
8
Reduced
24
Closed
11
Calls
$1.14M
Puts
$1.09M
Net Calls
+$46K
Net Calls Change
-$10K

Top Buyers

Rank Fund Capital Flow
1
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$244K
2
Jane Street
Jane Street
New York
+$150K
3
BWA
Blodgett Wealth Advisors
California
+$143K
4
E
Ergoteles
New York
+$54.7K
5
CL
CSS LLC
Illinois
+$50.2K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$831K
2
BCM
Bridgeway Capital Management
Texas
-$106K
3
Millennium Management
Millennium Management
New York
-$94.3K
4
Morgan Stanley
Morgan Stanley
New York
-$83.7K
5
GCP
GSA Capital Partners
United Kingdom
-$80K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
51
Wells Fargo
California
$6.58K +$21 +2 +0.4%
UBS Group
52
UBS Group
Switzerland
$6.25K -$26.2K -2,499 -83%
CPA
53
Capital Performance Advisors
California
$6.09K – – –
Ameriprise
54
Ameriprise
Minnesota
$6K -$105 -10 -2%
Belvedere Trading
55
Belvedere Trading
Illinois
$4.94K +$4.25K +405 New
JP Morgan Chase
56
JP Morgan Chase
New York
$4K -$4.19K -399 -58%
TRCT
57
Tower Research Capital (TRC)
New York
$3K -$1.83K -174 -46%
TIM
58
Tortoise Investment Management
New York
$2.44K – – –
GIA
59
GHP Investment Advisors
Colorado
$1.69K – – –
AA
60
Ancora Advisors
Ohio
$1K – – –
SWM
61
Spire Wealth Management
Virginia
$1K +$525 +50 New
ZIG
62
Zullo Investment Group
Pennsylvania
$610 – – –
National Bank of Canada
63
National Bank of Canada
Quebec, Canada
$605 – – –
BNP Paribas Financial Markets
64
BNP Paribas Financial Markets
France
$330 -$546 -52 -66%
PNC Financial Services Group
65
PNC Financial Services Group
Pennsylvania
$244 +$210 +20 New
Citigroup
66
Citigroup
New York
$86 -$1.29K -123 -95%
PAG
67
Private Advisor Group
New Jersey
$6 – – –
CS
68
Credit Suisse
Switzerland
$1 – – –
BCM
69
Bridgeway Capital Management
Texas
– -$106K -12,500 Closed
GCP
70
GSA Capital Partners
United Kingdom
– -$80K -9,431 Closed
LP
71
LMR Partners
United Kingdom
– -$41K -4,787 Closed
VF
72
Virtu Financial
New York
– -$31K -3,640 Closed
Balyasny Asset Management
73
Balyasny Asset Management
Illinois
– -$30K -3,534 Closed
Goldman Sachs
74
Goldman Sachs
New York
– -$29K -3,451 Closed
ProShare Advisors
75
ProShare Advisors
Maryland
– -$7K -839 Closed
1 2
3
4

CARM Hedge Fund Activity: Q4 2022 in Review

70 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q4 2022, worth a combined $19.8M — up 80% from $11M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new CARM positions and 11 closed out — a net gain of 2 holders — while 8 added to existing stakes and 24 trimmed.

The largest buyer was Acadian Asset Management, adding an estimated $244K. The largest seller was BlackRock, cutting an estimated $831K.

  • 70 institutional investors held Carisma Therapeutics (CARM) as of Q4 2022, up from 68 in Q3 2022.
  • Funds reported $19.8M of Carisma Therapeutics stock for Q4 2022, up 80% quarter-over-quarter.
  • 13 funds opened new Carisma Therapeutics positions in Q4 2022 and 11 closed out, a net change of +2 holders.
  • The largest Carisma Therapeutics buyer in Q4 2022 was Acadian Asset Management, an estimated $244K added.
  • The largest Carisma Therapeutics seller in Q4 2022 was BlackRock, an estimated $831K sold.

Based on aggregated 13F filings for Q4 2022.